Skip to main content
logo
Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
39.12
-1.34 (-3.31%)
Aug 28, 2026, 4:00 PM EDT - Market closed

Celldex Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.161.557.026.882.364.65
Revenue Growth
-97.27%-77.99%1.99%192.02%-49.32%-37.30%
Cost of Revenue
278.81245.07163.55118.0182.2653.31
Gross Profit
-278.65-243.53-156.53-111.13-79.9-48.66
Selling, General & Admin
47.1843.8438.5530.9127.220.49
Operating Expenses
47.1843.8438.5530.9127.220.49
Operating Income
-325.83-287.37-195.08-142.04-107.1-69.15
Interest & Investment Income
25.2828.6137.2213.112.910.51
EBT Excluding Unusual Items
-300.55-258.76-157.86-128.93-104.19-68.64
Legal Settlements
----12.5-15-
Other Unusual Items
----6.861.41
Pretax Income
-300.55-258.76-157.86-141.43-112.33-70.74
Income Tax Expense
------0.23
Net Income
-300.55-258.76-157.86-141.43-112.33-70.51
Net Income to Common
-300.55-258.76-157.86-141.43-112.33-70.51
Net Income Growth
------
Shares Outstanding (Basic)
696664484743
Shares Outstanding (Diluted)
696664484743
Shares Change
4.49%3.15%32.91%3.33%9.37%44.64%
EPS (Basic)
-4.33-3.90-2.45-2.92-2.40-1.64
EPS (Diluted)
-4.33-3.90-2.45-2.92-2.40-1.64
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-242.11-213.66-159.7-109.11-105.56-62.16
Free Cash Flow Per Share
-3.49-3.22-2.48-2.25-2.25-1.45
Operating Margin
-206220.25%-18599.81%-2778.89%-2063.66%-4543.74%-1486.73%
Profit Margin
-190220.89%-16748.03%-2248.76%-2054.76%-4765.59%-1516.04%
Free Cash Flow Margin
-153231.01%-13829.06%-2274.89%-1585.19%-4478.57%-1336.44%
EBITDA
-322.43-283.99-191.9-139.03-104.2-66.08
D&A For EBITDA
3.43.383.183.012.93.07
EBIT
-325.83-287.37-195.08-142.04-107.1-69.15
Revenue as Reported
0.161.557.026.882.364.65
SEC Filings: 10-K · 10-Q